Post job

Moximed CEO and executives

Executive Summary. Based on our data team's research, Anton Clifford Ph.D. is the Moximed's CEO. Moximed has 34 employees, of which 18 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Moximed executive team is 28% female and 72% male.
  • 55% of the management team is White.
  • 8% of Moximed management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Moximed?
Share your experience

Rate Moximed's leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Anton Clifford Ph.D.

Chief Executive Officer and Co-Founder

Anton Clifford Ph.D.'s LinkedIn

Joshua Makower

Founder

Joshua Makower's LinkedIn

Kevin Sidow

Board Member

Effective June 1, 2004, Kevin Sidow began his role as President and Chief Executive Officer for St. Francis Medical Technologies, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, Kevin oversaw the global orthopedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Kevin joined DePuy in March of 1998 as Midwest Area Vice President. He was promoted to Vice President, Sales, for DePuy Orthopaedics in October 1999 where he contributed significantly to the integration of the joints sales force while achieving record sales levels. He was promoted to President of DePuy Orthopaedics in August 2000. In April 2001, he was promoted to Worldwide President, DePuy Orthopaedics, ACE and Casting. In September 2003 he advanced to the position of Worldwide President, DePuy Inc. in addition to becoming a member of the MD&D Group Operating Committee. Prior to joining DePuy, Kevin was with Howmedica, then the orthopaedic division of Pfizer. SFMT’s first product, the X STOP® Interspinous Process Decompression (IPD) System for treatment of lumbar spinal stenosis, provides a minimally invasive alternative for spinal decompression. Founded in 1997, St. Francis Medical Technologies is a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. Headquartered in Alameda, CA, the Company has raised a total of $28 million in venture capital to date. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc.

Christine Barcelos

VP Corporate Operations

Christine Barcelos's LinkedIn

Keith Fong

VP Marketing and Business Development

Keith Fong's LinkedIn

Nancy Isaac

Regulatory Counsel and VP Quality

Nancy Isaac's LinkedIn

Luigi Bivi

Board Member

Luigi Bivi's LinkedIn

Brigitte Smith

Board Member

Arthur Franken

Board Member

Dan P Murray

Consulting CFO, Executive

Dan P Murray's LinkedIn

Seasoned Financial and Operational Executive, particularly skilled at growing startups into viable thriving businesses with exits that have included both IPOs and M&A. Have raised over $200M in venture capital and debt and have had exits in excess of $700M.

Do you work at Moximed?

Does leadership effectively guide Moximed toward its goals?

Moximed jobs

Moximed founders

Name & TitleBio
Anton Clifford Ph.D.

Chief Executive Officer and Co-Founder

Anton Clifford Ph.D.'s LinkedIn

Joshua Makower

Founder

Joshua Makower's LinkedIn

Kevin Sidow

Board Member

Effective June 1, 2004, Kevin Sidow began his role as President and Chief Executive Officer for St. Francis Medical Technologies, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, Kevin oversaw the global orthopedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Kevin joined DePuy in March of 1998 as Midwest Area Vice President. He was promoted to Vice President, Sales, for DePuy Orthopaedics in October 1999 where he contributed significantly to the integration of the joints sales force while achieving record sales levels. He was promoted to President of DePuy Orthopaedics in August 2000. In April 2001, he was promoted to Worldwide President, DePuy Orthopaedics, ACE and Casting. In September 2003 he advanced to the position of Worldwide President, DePuy Inc. in addition to becoming a member of the MD&D Group Operating Committee. Prior to joining DePuy, Kevin was with Howmedica, then the orthopaedic division of Pfizer. SFMT’s first product, the X STOP® Interspinous Process Decompression (IPD) System for treatment of lumbar spinal stenosis, provides a minimally invasive alternative for spinal decompression. Founded in 1997, St. Francis Medical Technologies is a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. Headquartered in Alameda, CA, the Company has raised a total of $28 million in venture capital to date. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc.

Moximed board members

Name & TitleBio
Joshua Makower

Founder

Joshua Makower's LinkedIn

Kevin Sidow

Board Member

Effective June 1, 2004, Kevin Sidow began his role as President and Chief Executive Officer for St. Francis Medical Technologies, Inc. Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, Kevin oversaw the global orthopedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Kevin joined DePuy in March of 1998 as Midwest Area Vice President. He was promoted to Vice President, Sales, for DePuy Orthopaedics in October 1999 where he contributed significantly to the integration of the joints sales force while achieving record sales levels. He was promoted to President of DePuy Orthopaedics in August 2000. In April 2001, he was promoted to Worldwide President, DePuy Orthopaedics, ACE and Casting. In September 2003 he advanced to the position of Worldwide President, DePuy Inc. in addition to becoming a member of the MD&D Group Operating Committee. Prior to joining DePuy, Kevin was with Howmedica, then the orthopaedic division of Pfizer. SFMT’s first product, the X STOP® Interspinous Process Decompression (IPD) System for treatment of lumbar spinal stenosis, provides a minimally invasive alternative for spinal decompression. Founded in 1997, St. Francis Medical Technologies is a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. Headquartered in Alameda, CA, the Company has raised a total of $28 million in venture capital to date. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc.

Luigi Bivi

Board Member

Luigi Bivi's LinkedIn

Brigitte Smith

Board Member

Arthur Franken

Board Member

John Nehra

Board Member

Lori Hu

Board Member

Lu Yoh-Chie

Board Member

Shahzad Malik

Board Member

Henry Plain

Board Member

Moximed executives FAQs

Zippia gives an in-depth look into the details of Moximed, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Moximed. The employee data is based on information from people who have self-reported their past or current employments at Moximed. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Moximed. The data presented on this page does not represent the view of Moximed and its employees or that of Zippia.

Moximed may also be known as or be related to Moximed, Moximed Inc, Moximed Inc., Moximed, Inc and Moximed, Inc.